NeoGenomics (NEO) Expected to Announce Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is anticipated to post its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $188.2460 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 8:30 AM ET.

NeoGenomics Stock Up 1.9%

NeoGenomics stock opened at $11.38 on Friday. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -12.93 and a beta of 1.58. NeoGenomics has a 52-week low of $4.72 and a 52-week high of $14.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.62 and a current ratio of 3.91. The firm has a 50 day moving average price of $12.18 and a two-hundred day moving average price of $9.99.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Leerink Partners set a $14.00 price objective on NeoGenomics in a research report on Tuesday, October 28th. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a research note on Wednesday, January 7th. Zacks Research raised shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price target on shares of NeoGenomics in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $12.00.

Insider Activity at NeoGenomics

In other news, COO Warren Stone sold 22,128 shares of NeoGenomics stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total transaction of $276,600.00. Following the sale, the chief operating officer directly owned 121,631 shares in the company, valued at $1,520,387.50. The trade was a 15.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Alicia C. Olivo sold 20,916 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total transaction of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares of the company’s stock, valued at approximately $372,996. The trade was a 40.22% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On NeoGenomics

Large investors have recently modified their holdings of the stock. Loomis Sayles & Co. L P bought a new position in NeoGenomics during the fourth quarter valued at $19,182,000. American Capital Management Inc. lifted its holdings in NeoGenomics by 120.9% during the third quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after purchasing an additional 1,283,390 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in NeoGenomics during the second quarter worth about $6,071,000. First Light Asset Management LLC increased its stake in shares of NeoGenomics by 13.3% in the second quarter. First Light Asset Management LLC now owns 6,846,432 shares of the medical research company’s stock worth $50,047,000 after purchasing an additional 803,610 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of NeoGenomics by 246.8% during the 2nd quarter. Squarepoint Ops LLC now owns 735,473 shares of the medical research company’s stock valued at $5,376,000 after buying an additional 523,407 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.